Leukemia header  
Leukemia symptom graphic

Leukemia Information image
Leukemia Transmission
Leukemia image

 

Transfer Factor                  Transfer Factor Science       History of Transfer Factor  Autoimmune Diseases | Immune Disorders                      Common Cold                  Influenza Information               Bird Flu & Transfer Factor      Migraine Headache Symptoms  Migraine Headache Treatment   Mono | Mononucleosis            Tuberculosis Symptoms         Tuberculosis Treatment      Allergies Information          Eczema Management       Psoriasis Symptoms          Shingles Symptoms           Asthma Information            Cancer and NK cells             Bone Cancer Information        Brain Tumor | Cancer          Breast Cancer Symptom    Cervical Cancer Symptom Cervical Cancer Treatment   Colon Cancer Symptom         Colon Cancer Treatment    Esophageal Cancer                 Leukemia Information             Leukemia Virus Information   Leukemia Treatment               Liver Cancer Information         Lung Cancer Symptoms       Lymph Node Cancer       Mesothelioma - Asbestos Lung Cancer                                 Malignant Mesothelioma 1         Malignant Mesothelioma 2 Ovarian Cancer Symptoms   Pancreatic Cancer             Pancreatic Cancer & Diabetes Prostate Cancer Information      Skin Cancer Symptoms   Stomach Cancer Symptom Testicular Cancer Symptom Anemia Symptoms         Diabetes Causes & Types   Diabetes Symptoms         Manage & Monitor Diabetes  Diabetes & Pancreatic Cancer Dealing with Diabetes          Hepatitis Symptoms              Hepatitis A Information       Hepatitis B Information    Hepatitis C Information       Graves Disease Symptoms    Hashimoto Disease 1      Hashimoto Disease 2      Hyperthyroidism Symptoms     Hypothyroid Symptoms    Neutropenia Information       Angina Symptom Information   Angina Treatment Information High Blood Pressure            Heart Attack Information Coronary Heart Disease        Heart Attack Prevention      Stroke Symptom Information    High Blood Pressure & Stroke Hypertension and Stroke       Acid Reflux Disease           Celiac Disease Information  Celiac Disease Treatment       Crohn's Disease Symptom      Irritable Bowel Syndrome (IBS)   Fibromyalgia Information        Lupus Disease Information     Lupus Disease Study Results  Myasthenia Gravis Information Osteoarthritis Symptoms      Psoriatic Arthritis Information     Rheumatoid Arthritis Information Anxiety Disorder Information  Autism Symptoms Information  Bipolar Disorder Information      Bipolar Disorder Diagnosis 1 Bipolar Disorder Diagnosis 2     Depression Symptoms           Depression Treatment 1           Depression Treatment 2        Schizophrenia Information      Multiple Sclerosis Symptoms Menopause Information           HRT Risks & Benefits
HRT Research
HRT and Breast Cancer        Premarin Menopause Drug  
PMS and You                         Genital Herpes Information 1 Genital Herpes Information 2     Genital Herpes Information 3     HIV | AIDS Prevention     

Immune System & Diseases

Transfer Factor & Immune Function that affect Cancer

Natural Killer Cells in Human Cancer

Human Carcinongens

Major Side Effects of Chemotherapy

Chemotherapy Side Effects Studies comparing the impact of different antiemetics on HRQL

Immune System Supplement  Increase your natural killer (NK) cells activities with enhanced transfer factor, natural immune booster for the fight against cancer cells.

Glucose Control Tablet

Pycnogenol (French maritime pine tree extract) Benefit for Diabetes

Diabetes & Pycnogenol Double Blinded Study

Custom Search

 

 

Leukemia Transmission

Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL)

Masao Matsuoka, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan, Retrovirology 2005, 2:27 doi:10.1186/1742-4690-2-27
© 2005 Matsuoka; licensee BioMed Central Ltd., This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background of Human T-cell Leukemia Virus Type I infection and the onset of Adult T-cell Leukemia

History of humans and Human T-cell Leukemia Virus Type 1

How does Human T-cell Leukemia Virus type 1 spread in humans?

How does Human T-cell Leukemia Virus Type 1 replicate and increase its copy number?

4. How does Human T-cell Leukemia Virus Type 1 (HTLV-I) transmit and replicate in vivo?

Receptor and transmission of Human T-cell Leukemia Virus type 1

Human T-cell Leukemia Virus Type 1 can infect various types of cells, such as T-lymphocytes, B-lymphocytes, monocytes and fibroblasts [46]. Glucose transporter 1 (GLUT-1) has been identified as a receptor for Human T-cell Leukemia Virus Type 1 and this receptor is ubiquitously expressed on cell surfaces [47]. However, the Human T-cell Leukemia Virus Type 1 provirus is mainly detected in CD4-positive lymphocytes, with about 10% in CD8-positive T-lymphocytes [48]. This situation possibly arises because Tax mainly induces the increase of CD4-positive T-lymphocytes in vivo by enhanced proliferation and suppressed apoptosis.

In Human T-cell Leukemia Virus Type 1-infected individuals, no virions are detected in the serum. In addition, the infectivity of free virions is very poor compared with that of infected cells. These findings suggest that Human T-cell Leukemia Virus Type 1 is spread by cell-to-cell transmission, rather than by free virions. In vitro analyses of Human T-cell Leukemia Virus Type 1-infected cells revealed that HTLV-I-infected cells form "virological synapses" with uninfected cells. Contact between an infected cell and a target cell induces the accumulation of the viral proteins Gag and Env, viral RNA and microtubules, and the viral complex subsequently transfers into the target cell [49]. Human T-cell Leukemia Virus type 1 also spreads in a cell-to-cell manner via such virological synapses in vivo.

Human T-cell Leukemia Virus Type 1 is mainly transmitted via three routes: 1) mother-to-infant transmission (mainly through breast feeding) [50]; 2) sexual transmission (mainly from male-to-female); and 3) parenteral transmission (blood transfusion or intravenous drug use) [12]. In either route, HTLV-I-infected cells are essential for transmission. This was supported by the findings that fresh frozen plasma from carriers did not cause transmission [51] and freeze-thawing of breast milk reduced vertical transmission [52].

Provirus load and transmission

The provirus load varies more than 1000-fold among asymptomatic carriers [53]. Since most infected cells are considered to have one copy of the provirus, the provirus load indicates the percentage of infected cells among lymphocytes. The provirus load is relatively constant during the latent period [53]. Analysis of naive individuals who seroconvert after marrying an Human T-cell Leukemia Virus Type 1-seropositive spouse demonstrated that the proviral gp46 sequences are identical among married couples. This finding confirmed that HTLV-I is transmitted from a seropositive individual to an uninfected spouse. The provirus loads frequently differ between couples despite infection by the same HTLV-I virus, indicating that the number of infected cells is determined by host factors rather than virus itself [54].

Why does Human T-cell Leukemia Virus Type 1 increase the number of infected cells by the pleiotropic actions of Tax? The provirus load in peripheral blood mononuclear cells (PBMCs) is well correlated with that in breast milk, and a higher provirus load in breast milk increases the risk of vertical transmission of HTLV-I [55,56]. Similarly, a higher provirus load in PBMCs may be associated with a higher risk of sexual transmission. Thus, an increase in the number of infected cells by the actions of accessory genes, especially tax, facilitates transmission. Therefore, HTLV-I has strategies that increase the number of HTLV-I-infected cells via the action of accessory gene products, thereby increasing the chance of transmission.

Clonal expansion of Human T-cell Leukemia Virus Type 1-infected cells

After Human T-cell Leukemia Virus Type 1 infection, viral proteins such as Tax protein promote the proliferation of infected cells and also inhibit apoptosis by their pleiotropic actions. Since the HTLV-I provirus is randomly integrated into the host genome, the identification of integration sites enables to identify each infected clone, and to trace the kinetics of infected cells in vivo. Analyses using inverse PCR, which can identify the integration sites of the HTLV-I provirus, revealed that the proliferation of infected cells is oligoclonal, and that infected cells persistently survive in vivo [57-59]. Importantly, such clonal expansion in carriers is directly associated with the onset of Adult T-cell Leukemia [60]. Thus, the viral strategies to increase the number of HTLV-I-infected cells work efficiently in most carriers without any adverse effects. However, the increased number of infected cells causes an excess immune reaction, leading to inflammatory diseases, HAM/TSP, infective dermatitis [61] or HTLV-I-associated uveitis [62]. Moreover, such prolonged proliferation of infected CD4-positive T-lymphocytes results in the onset of ATL in some carriers after a long latent period.

Inactivation of Tax expression in Adult T-cell Leukemia (ATL) cells

As mentioned above, Tax expression confers advantages and disadvantages on Human T-cell Leukemia Virus Type 1-infected cells. Although the proliferation of infected cells is promoted by Tax expression, CTLs attack the Tax-expressing cells since Tax is their major target [63]. In HTLV-I-infected cells, Rex, p30 and HBZ suppress Tax expression. On the other hand, loss of Tax expression is frequently observed in leukemic cells. Three mechanisms have been identified for inactivation of Tax expression: 1) genetic changes of the tax gene (nonsense mutations, deletions or insertions) [64,65]; 2) DNA methylation of the 5'-LTR [65,66]; and 3) deletion of the 5'-LTR (Figure 2) [67]. Among fresh leukemic cells isolated from ATL patients, about 60% of cases do not express the tax gene transcript. Interestingly, Adult T-cell Leukemia cells with genetic changes of the tax gene expressed its transcripts, suggesting that ATL cells do not silence the transcription when the tax gene is abortive [65]. Loss of Tax expression gives ATL cells advantage for their survival since they can escape from CTLs.

Longer lifespan of Human T-cell Leukemia Virus type 1-infected cells and cancer

Lymphoid malignancy with a T-cell origin is rare compared with B-cell malignancy. Adult T-cell Leukemia shares hematological, pathological and immunological features with cutaneous T-cell lymphoma (CTCL; Sezary syndrome and Mycosis fungoides). The frequency of CTCL in Japan is estimated to be one/million/year. On the other hand, the frequency of ATL among carriers is estimated to be 1000/million/year. From these data, HTLV-I infection is estimated to increase the risk of T-cell malignancy by up to 1000-fold in carriers.

Human T-cell Leukemia Virus Type 1 infection confers a long lifespan on the infected cells due to the pleiotropic actions of Tax, resulting in increased numbers of infected cells. Such infected cells are essential for the transmission of HTLV-I. This strategy to increase the number of infected cells in vivo is thought to increase the incidence of cancer in T-cells. What is the mechanism for this oncogenesis? DNA methylation is known to be associated with aging. Some genes are hypermethylated in older people, indicating that DNA hypermethylation is a physiological phenomenon in some genes. Under normal circumstances, T-lymphocytes survive for several years, and long-lived T-lymphocytes with disordered methylation should be replaced. However, HTLV-I-infected T-cells are considered to survive and accumulate abnormal methylation. The process of oncogenesis is similar to that of evolution [68]. The infected cells that are suitable for survival should be selected in vivo, and epigenetic and genetic changes of the genome play critical roles in this selection. Accumulating alterations of the host genome transform the HTLV-I-infected cells into ATL cells, and also enable ATL cells to proliferate in the absence of Tax expression (Figure 2). In the provirus, DNA methylation of the 5'-LTR silences viral transcription in leukemic cells, which facilitates the escape of ATL cells from the host immune system [65].

5. Somatic alterations in Adult T-cell Leukemia cells

As described, some Adult T-cell Leukemia cells can proliferate without functional Tax protein, suggesting that somatic (genetic and epigenetic) alterations cause transcriptional or functional changes to the host genes. The p53 gene is frequently mutated in various cancers, and these mutations are associated with disease progression and a poor prognosis. The mutation rate of the p53 gene in ATL cells has been reported to be 36% (4/11) and 30% (3/10) [69-71]. The p16 gene is an inhibitor of cyclin-dependent kinase 4/6, and blocks the cell cycle. Genetic changes in this gene (deletion in most cases) have been described in many types of cancer cells. Deletion of the p16 gene has also been reported in ATL cells [72]. Moreover, DNA methylation of the promoter region of the p16 gene is also implicated in the suppression of p16 [73]. In addition, genetic changes in the p27KIP1, RB1/p105 and RB2/p130 genes have been reported in ATL, although they are relatively rare: 2/42 (4.8%) for the p27KIP1 gene; 2/40 (5%) for the RB1/p105 gene; and 1/41 (2.4%) for the RB2/p130 gene) [74]. The fact that higher frequencies of genetic changes in these tumor suppressor genes are observed among aggressive forms of ATL suggests that such genetic changes are implicated in disease progression.

Fas antigen was the first identified death receptor. It transduces the death signal by binding of its ligand, Fas ligand (FasL). Adult T-cell Leukemia cells highly express Fas antigen on their cell surface [75], and are highly susceptible to death signals mediated by agonistic antibodies to Fas antigen, such as CH-11. Genetic changes of Fas gene in ATL cells, which confer resistance to the Fas-mediated signal, have been reported [76,77]. Normal activated T-lymphocytes express FasL as well as Fas antigen. Apoptosis induced by autocrine mechanisms is designated activation-induced cell death (AICD) and this controls the immune response [78]. Although ATL cells express Fas antigen, they do not produce FasL, thereby enabling ATL cells to escape from AICD. Attempts to isolate hypermethylated genes from ATL cells identified the EGR3 gene as a hypermethylated gene compared to PBMCs from carriers [79]. EGR3 is a transcriptional factor with a zinc finger domain, that is essential for transcription of the FasL gene [80]. The finding that EGR3 gene transcription is silenced in ATL cells could account for the loss of FasL expression, and the escape of ATL cells from AICD. Thus, alterations of the Fas (genetic) and EGR3 (epigenetic) genes are examples of ATL cell evolution in vivo.

Disordered DNA methylation has been identified in the genome of Adult T-cell Leukemia cells compared with that of PBMCs from carriers: hypomethylation is associated with aberrant expression of the MEL1S gene [81], while hypermethylation silences transcription of the p16 [73], EGR3 and KLF4 genes as well as many others [79]. It is reasonable to consider that other currently unidentified genes are involved in such alterations of the genome in ATL cells, and play roles in leukemogenesis.

Transcriptome analyses using DNA microarrays have revealed transcriptional changes that are specific to Adult T-cell Leukemia cells. Among 192 up-regulated genes, the expressions of the tumor suppressor in lung cancer 1 (TSLC1), caveolin 1 and prostaglandin D2 synthase genes were increased more than 30-fold in fresh ATL cells compared with normal CD4+ and CD4+, CD45RO+ T-cells [82]. TSLC1 is a cell adhesion molecule that acts as a tumor suppressor in lung cancer. Although TSLC1 is not expressed on normal T-lymphocytes, all acute ATL cells show ectopic TSLC1 expression. Enforced expression of TSLC1 enhances both the self-aggregation and adhesion abilities to vascular endothelial cells in ATL cells. Thus, TSLC1 expression is implicated in the adhesion or infiltration of ATL cells. By screening a retrovirus cDNA library from ATL cells, a gene with oncogenic potency was identified in NIH3T3 cells, and designated the Tgat gene [83].

Ectopic expression of the Tgat gene is observed in aggressive forms of Adult T-cell Leukemia, and in vitro experiments showed that its expression is associated with an invasive phenotype.

Immune control of Human T-cell Leukemia Virus Type 1 infection

Pathogenesis of Human T-cell Leukemia Virus Type 1 infection

Treatment of Adult T-cell Leukemia - the remaining mission and challenges

Two human retroviruses - Human T-cell Leukemia Virus Type 1 and HIV-1

Resources
12.   Blattner WA, Gallo RC: Epidemiology of HTLV-I and HTLV-II infection.
In Adult T-cell leukemia. Edited by: Takahashi K. New York, Oxford University Press; 1994:p.45-90.
    Return to citation in text: [1]
 
46.   Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira J, Iwamasa T, Goto I, Yamamoto N: In vivo infection of human T-cell leukemia virus type I in non-T cells.
Virology 1993, 196:25-33.
    Return to citation in text: [1]
 
47.   Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL: The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.
Cell 2003, 115:449-459.
    Return to citation in text: [1]
 
48.   Yasunaga J, Sakai T, Nosaka K, Etoh K, Tamiya S, Koga S, Mita S, Uchino M, Mitsuya H, Matsuoka M: Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.
Blood 2001, 97:3177-3183.
    Return to citation in text: [1]
 
49.   Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton.
Science 2003, 299:1713-1716.
    Return to citation in text: [1]
 
50.   Hino S: Primary prevention of ATL.
In Two decades of adult T-cell leukemia and HTLV-I research. Edited by: Sugamura K, Uchiyama T, Matsuoka M and Kannagi M. Tokyo, Japan Sicentific Societies Press; 2003:241-251.
    Return to citation in text: [1]
 
51.   Okochi K, Sato H, Hinuma Y: A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients.
Vox Sang 1984, 46:245-253.
    Return to citation in text: [1]
 
52.   Ando Y, Ekuni Y, Matsumoto Y, Nakano S, Saito K, Kakimoto K, Tanigawa T, Kawa M, Toyama T: Long-term serological outcome of infants who received frozen-thawed milk from human T-lymphotropic virus type-I positive mothers.
J Obstet Gynaecol Res 2004, 30:436-438.
    Return to citation in text: [1]
 
53.   Etoh K, Yamaguchi K, Tokudome S, Watanabe T, Okayama A, Stuver S, Mueller N, Takatsuki K, Matsuoka M: Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors.
Int J Cancer 1999, 81:859-864.
    Return to citation in text: [1] [2]
 
54.   Iga M, Okayama A, Stuver S, Matsuoka M, Mueller N, Aoki M, Mitsuya H, Tachibana N, Tsubouchi H: Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses.
J Infect Dis 2002, 185:691-695.
    Return to citation in text: [1]
 
55.   Li HC, Biggar RJ, Miley WJ, Maloney EM, Cranston B, Hanchard B, Hisada M: Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I.
J Infect Dis 2004, 190:1275-1278.
    Return to citation in text: [1]
 
56.   Hisada M, Maloney EM, Sawada T, Miley WJ, Palmer P, Hanchard B, Goedert JJ, Manns A: Virus markers associated with vertical transmission of human T lymphotropic virus type 1 in Jamaica.
Clin Infect Dis 2002, 34:1551-1557.
    Return to citation in text: [1]
 
57.   Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Mueller N, Takatsuki K, Matsuoka M: Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo.
Cancer Res 1997, 57:4862-4867.
    Return to citation in text: [1]
 
58.   Cavrois M, Leclercq I, Gout O, Gessain A, Wain-Hobson S, Wattel E: Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy.
Oncogene 1998, 17:77-82.
    Return to citation in text: [1]
 
59.   Matsuoka M: Human T-cell leukemia virus type I and adult T-cell leukemia.
Oncogene 2003, 22:5131-5140.
    Return to citation in text: [1]
 
60.   Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka G, Kubuki Y, Mueller N, Hsieh CC, Tachibana N, Tsubouchi H: Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers.
Int J Cancer 2004, 110:621-625.
    Return to citation in text: [1]
 
61.   LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W: Infective dermatitis of Jamaican children: a marker for HTLV-I infection.
Lancet 1990, 336:1345-1347.
    Return to citation in text: [1]
 
62.   Nakao K, Ohba N, Matsumoto M: Noninfectious anterior uveitis in patients infected with human T-lymphotropic virus type I.
Jpn J Ophthalmol 1989, 33:472-481.
    Return to citation in text: [1]
 
63.   Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, et al.: Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV- I-infected cells.
Int Immunol 1991, 3:761-767.
    Return to citation in text: [1]
 
64.   Furukawa Y, Kubota R, Tara M, Izumo S, Osame M: Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia.
Blood 2001, 97:987-993.
    Return to citation in text: [1]
 
65.   Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells.
Int J Cancer 2004, 109:559-567.
    Return to citation in text: [1] [2] [3] [4]
 
66.   Koiwa T, Hamano-Usami A, Ishida T, Okayama A, Yamaguchi K, Kamihira S, Watanabe T: 5'-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo.
J Virol 2002, 76:9389-9397.
    Return to citation in text: [1]
 
67.   Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, Takatsuki K: Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia.
Blood 1996, 88:3065-3073.
    Return to citation in text: [1]
 
68.   Tomlinson I, Bodmer W: Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog.
Nat Med 1999, 5:11-12.
    Return to citation in text: [1]
 
69.   Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP: Mutations of the p53 gene in adult T-cell leukemia.
Blood 1992, 79:477-480.
    Return to citation in text: [1]
 
70.   Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM: Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations.
Blood 1992, 80:3205-3216.
    Return to citation in text: [1]
 
71.   Nishimura S, Asou N, Suzushima H, Okubo T, Fujimoto T, Osato M, Yamasaki H, Lisha L, Takatsuki K: p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia.
Leukemia 1995, 9:598-604.
    Return to citation in text: [1]
 
72.   Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.
Blood 1995, 85:2699-2704.
    Return to citation in text: [1]
 
73.   Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M: Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia.
Cancer Res 2000, 60:1043-1048.
    Return to citation in text: [1] [2]
 
74.   Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP: Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma.
Blood 1995, 86:1924-1930.
    Return to citation in text: [1]
 
75.   Nagata S: Fas ligand-induced apoptosis.
Annu Rev Genet 1999, 33:29-55.
    Return to citation in text: [1]
 
76.   Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M: Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.
Blood 1998, 91:3935-3942.
    Return to citation in text: [1]
 
77.   Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T, Atogami S, Tsukasaki K, Tomonaga M, Kamihira S: Fas gene mutation in the progression of adult T cell leukemia.
J Exp Med 1999, 189:1063-1071.
    Return to citation in text: [1]
 
78.   Krueger A, Fas SC, Baumann S, Krammer PH: The role of CD95 in th